IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | $7.00M |
| Net Income (Most Recent Fiscal Year) | $-274.48M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.24 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4740.03% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -31.42% |
| Return on Assets (Trailing 12 Months) | -29.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.88 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.36 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 87.64M |
| Free Float | 85.45M |
| Market Capitalization | $2.15B |
| Average Volume (Last 20 Days) | 0.80M |
| Beta (Past 60 Months) | 0.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |